The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

A transdermal patch is provided, wherein the patch comprises a cross-linked poly(ethylene oxide) hydrogel loaded with naltrexone, or a pharmaceutically acceptable salt or solvate thereof, and an occlusive adhesive tape. The poly(ethylene oxide) hydrogel has a crosslink density of at least 4.5×10.sup.−4 mol cm.sup.−3 and not more than 16×10.sup.−4 mol cm.sup.−3. Also provided are methods for preparing naltrexone-loaded cross-linked poly(ethylene oxide) hydrogels, transdermal patches for use as a medicament, for example in the treatment of a specified condition with LDN therapy.

The present invention relates to a topical anti-inflammatory pharmaceutical composition comprising Zileuton. Furthermore, the present invention relates to uses of such composition. Moreover, the present invention relates to methods of preparing a topical anti-inflammatory pharmaceutical composition comprising Zileuton.

A use of a CD200 extracellular domain protein or a fusion protein formed from a CD200 extracellular domain protein and an Fc fragment in preparing a drug for treating psoriasis is disclosed.

A use of a CD200 extracellular domain protein or a fusion protein formed from a CD200 extracellular domain protein and an Fc fragment in preparing a drug for treating psoriasis is disclosed.

The present invention features agents for treating autoimmune diseases and other conditions characterized by pathological immune responses, and for preventing or reversing immune recognition of neoantigens associated with therapeutic proteins or gene therapy vectors.

The present invention features agents for treating autoimmune diseases and other conditions characterized by pathological immune responses, and for preventing or reversing immune recognition of neoantigens associated with therapeutic proteins or gene therapy vectors.

The present invention relates to compositions of recombinant polynucleic acid constructs comprising at least one nucleic acid sequence encoding an siRNA capable of binding to a target mRNA and at least one nucleic acid sequence encoding a gene of interest. Also disclosed herein is use of the compositions in treating a disease or a condition and in simultaneously modulating expression of two or more genes.

The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug. ##STR00001##